IMS data reportedly show 834 new patient starts as of the week ending December 20.
"Assuming new starts increasing to 1000/wk by end of the year and gross to net of 15%, we [calculate] Q4 sales at $61M. If new starts rise to 2000/wk by year end, assuming a gross to net of 15%, we [calculate] Q4 sales at $98M," analyst Robyn Karnauskas notes.
Buy rating maintained.
Price target is $95.